We are live on ! Find out more
IOBT

IO Biotech
IOBT

Delisted

IOBT was delisted on the 6th of April, 2026.

Back to rankings

17 hedge funds and large institutions have $26.1M invested in IO Biotech in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 17 → 17 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

1.26% less ownership

Funds ownership: 49.55% → 48.29% (-1.3%)

21% less capital invested

Capital invested by funds: $32.8M → $26.1M (-$6.77M)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
17
Holders Change
–
Holders Change %
0%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.49M
2
Citadel Advisors
Citadel Advisors
Florida
+$117K
3
Renaissance Technologies
Renaissance Technologies
New York
+$93.5K
4
Morgan Stanley
Morgan Stanley
New York
+$35.2K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$2.59M
2
Capital World Investors
Capital World Investors
California
-$1.63M
3
NM
Newtyn Management
New York
-$101K
4
PVH
Psagot Value Holdings
Israel
-$94K
5
Millennium Management
Millennium Management
New York
-$1.59K

IOBT Hedge Fund Activity: Q1 2023 in Review

17 of the 6,279 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q1 2023, worth a combined $26.1M — down 21% from $32.8M a quarter earlier.

Fund positioning in IOBT was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 3 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $3.49M. The largest seller was RA Capital Management, exiting entirely with an estimated $2.59M sold.

  • 17 institutional investors held IO Biotech (IOBT) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $26.1M of IO Biotech stock for Q1 2023, down 21% quarter-over-quarter.
  • 2 funds opened new IO Biotech positions in Q1 2023 and 2 closed out, a net change of 0 holders.
  • The largest IO Biotech buyer in Q1 2023 was Point72 Asset Management, an estimated $3.49M added.
  • The largest IO Biotech seller in Q1 2023 was RA Capital Management, an estimated $2.59M sold.

Based on aggregated 13F filings for Q1 2023.